Tariff-related Litigation Update – 7/18
IEEPA Tariffs & Legal Challenge Update (7/18/2025)
This members-only briefing details reciprocal tariffs under Executive Order 14257 (as amended), alongside the newly threatened “fentanyl” tariffs—35% on Canadian and 30% on Mexican goods—which could take effect as early as August 1 under IEEPA. It also summarizes the latest judicial developments in key challenges—including V.O.S. Selections (government’s reply brief now filed), Oregon (Fed. Cir. May 28, 2025), Learning Resources (D.C. Cir. May 30 & U.S. June 17, 2025), Emily Ley Paper, Inc. (Ct. Int’l Trade May 23, 2025), Webber (D. Mont. Apr. 4, 2025), and California (N.D. Cal. Apr. 16, 2025).
Related Reading
News / Global & Trade / Tariffs
ICYMI: AdvaMed’s Scott Whitaker on Supreme Court Tariffs Decision, Next Steps
February 23, 2026
Scott Whitaker, president and CEO of AdvaMed, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
February 26, 2026
1:00 PM – 2:00 PM
Recent court decision may affect your tariff exposure and supply chain strategy. Join us for a live emergency briefing.
News / Global & Trade / Supply Chain / Tariffs
AdvaMed Supports United States-Mexico-Canada Agreement Renewal
February 12, 2026
WASHINGTON—AdvaMed, the Medtech Association, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker, AdvaMed president and CEO, made the following comment on the renewal.
Resource / AdvaMed Advancements / Global & Trade / Tariffs
AdvaMed Plays Tariff Chess, Trump Plays Checkers
February 4, 2026
As tariff uncertainty continues in 2025, AdvaMed plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs
AdvaMed® Advancements: Q4 2025 Report
January 27, 2026
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
News / China / Global & Trade / Supply Chain / Tariffs
AdvaMed Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
November 3, 2025
WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q3 2025 Report
October 31, 2025
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs / Workforce Advancement
The Economic Impact of the Medical Technology Industry 2024
October 27, 2025
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy